Navigation Links
Abraxis BioScience Presents Data from Pre-Clinical Study That,Provide Evidence for Chemotherapy-Induced Angiogenesis and,Rationale for Combining nab-Paclitaxel (Abraxane) with,Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, discussed results from two pre-clinical studies that provide evidence for chemotherapy induced angiogenesis and rationale for combining nab-paclitaxel (ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)) with VEGF inhibitor drugs like bevacizumab (Avastin(R)) at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles.

The first of two pre-clinical studies investigating mechanistic aspects of chemotherapy induced angiogenesis showed for the first time that nab-paclitaxel, as well as standard chemotherapies like solvent-based paclitaxel (Taxol(R)) and doxorubicin, can trigger reactionary angiogenesis with concomitant increased secretion from tumors of angiogenic factors, such as VEGF. This 'reactionary angiogenesis' provides a strong mechanistic rationale for combination of nab-paclitaxel therapy with the VEGF inhibitor drugs, such as bevacizumab, to enhance the antitumor response. (Abstract #4636; Investigation of Chemotherapy-induced Tumor Angiogenesis: Rationale for Combination of nab-paclitaxel with Anti-VEGF Therapy).

The second pre-clinical study, which investigated tumor regression and metastasis, found that the combination of nab-paclitaxel with bevacizumab in breast cancer tumor models showed significantly enhanced anti-tumor response with a significantly reduced frequency of metastasis to the lymph nodes and lungs as compared to single agent therapy. (Abstract #2201; The Role of VEGF in Chemoprotection and Tumor Metastasis: Rationale for Combination of nab-paclitaxel and bevacizumab). Both studies demonstrate the potential of nab-paclitaxel in combination with bevacizumab as an effective antitumor agent.

Abraxis continues to explore the rol
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Abraxis BioScience Presents Results from Pre-Clinical Study That Demonstrates nab-Rapamycins Robust Antitumor Properties and Ability to Target Intracellular Sites Such as the mTOR Pathway
2. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:5/23/2013)... , May 23, 2013  Every day, their baby ... air to his lungs. April and Bryan Gionfriddo ... predictions weren,t true. "Quite a few doctors said ... alive," says April Gionfriddo , about her ... Anything that would work, we would take it and run ...
(Date:5/23/2013)... , May 23, 2013   Direct to ... mastectomy is an appropriate option for many women ... surgically reduce their breast cancer risk, or with ... expansion process and a second surgery to insert ... the same surgery as mastectomy can be a ...
(Date:5/23/2013)... TEL AVIV, Israel , May 23, 2013 ... of BrainTech Israel 2013 , Israel,s ... take place on October 14 th -15 th in ... 2 nd most innovative city in the world by ... the "Start-up Nation." BrainTech Israel 2013 will showcase ...
Breaking Medicine Technology:Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 2Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
(Date:5/23/2013)... of borderline personality disorder often mimic traits of ... researchers in Canada say they have identified a ... disorder: a tendency to misinterpret emotions expressed by ... facial emotions and will see a negative emotion ... clinical neuropsychologist and assistant professor at the University ...
(Date:5/23/2013)... (HealthDay News) -- A shortage of a critical tuberculosis ... the United States to contain the spread of the ... drug, isoniazid (INH), was first used in 1951 and ... core of any first-line treatment for tuberculosis (TB). Patients ... according to the U.S. Centers for Disease Control and ...
(Date:5/23/2013)... at Emory Vaccine Center have shown that an immune ... responses in mice against viral infections. , The results ... , "Our findings highlight how IL-21 could be important ... Ata Ur Rasheed Mohammed, PhD, the first author of ... director of the Emory Vaccine Center and a Georgia ...
(Date:5/23/2013)... Netsmart today announced it is ... healthcare information technology (HIT) providers for 2013. , The HCI ... Healthcare Informatics magazine. Netsmart’s ranking of #49 is ... continued growth is largely due to our commitment to helping ... healthcare where resources are scarce, the demand for care is ...
(Date:5/23/2013)... examining outcomes for advanced heart-failure patients over the ... the increased availability and use of new therapies, ... caused by the rapid onset of severe abnormal ... the team found that even today, with these ... than three years after being diagnosed with advanced ...
Breaking Medicine News(10 mins):Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3Health News:Shortage of Key Drug Hampering U.S. Efforts to Control TB: Report 2Health News:Vaccine blackjack: IL-21 critical to fight against viral infections 2Health News:Netsmart Named to Healthcare Informatics Top 100 List 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 2Health News:Death rates decline for advanced heart failure patients, but outcomes are still not ideal 3
... how cocaine corrupts the brain and becomes addictive. These findingsthe ... cocaine rewardwere published in Science on October 15. ... treating those addicted to the drug. Led by ... Neuroscience at Mount Sinai School of Medicine and first author ...
... The US Department of Defense (DOD) has awarded a ... Research and the University of Cincinnati to further develop ... severe brain injury. Management of severe brain trauma ... critical first few hours and days after an injury. ...
... , MONDAY, Oct. 18 (HealthDay News) -- Canadian ... the so-called swine flu -- to be very severe this ... of 50, especially those with chronic health conditions, get immunized ... results of blood tests given to 1,127 people in the ...
... Institute has awarded a $4.37 million grant to Jeffrey ... to advance a recent scientific laboratory discovery into a ... under the American Recovery and Reinvestment Act, will help ... by Toretsky and his team a critical step ...
... Texas (October 18, 2010) The latest colorectal ... Gastroenterology,s (ACG) 75th Annual Scientific meeting in San ... evidence that suggests significant disparity in colorectal cancer ... the first in a series of studies investigating ...
... Antonio, Texas (October 18, 2010) Investment in screening ... 50 and 64, is needed to reduce the costs ... the results of a new study, "Cost-Savings to Medicare ... unveiled today at the American College of Gastroenterology,s (ACG) ...
Cached Medicine News:Health News:Mount Sinai researchers discover why cocaine is so addictive 2Health News:Feinstein Institute to share $5M US Department of Defense grant 2Health News:H1N1 Unlikely to Cause Flu Pandemic in 2010-11: Analysis 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 2Health News:$4.37 million NCI grant accelerates recent laboratory finding in Ewing's sarcoma 3Health News:Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer 2Health News:Notable racial disparities in diagnosis, treatment and outcomes of colorectal cancer 3Health News:Investment in CRC screening targeting pre-medicare population could cut medicare treatment costs 2
Highly concentrated daily cleaner with Microclens beads for superior cleaning action....
Optimum Extra Strength cleaner is a sterile non-preserved cleaning solution for use with fluorosilicone acrylate and silicone acrylate rigid gas permeable (RGP) and all hard contact lenses of any pol...
5 inch (12.7 cm), 2 x 5 mm blade....
DIX foreign body spud 4 3/4 inches, 1.7 x 15 mm blade....
Medicine Products: